CHRONIC VIRAL HEPATITIS: MODERN PERSPECTIVES ON EPIDEMIOLOGY, PATHOGENESIS, DIAGNOSTICS AND ANTIVIRAL TREATMENT STRATEGIES (A COMPREHENSIVE SCIENTIFIC REVIEW)

Shakhnoza Bakhadirovna Rakhmatullaeva; Akhmedova Oydin Anvarovna

Authors

Shakhnoza Bakhadirovna Rakhmatullaeva Author
Akhmedova Oydin Anvarovna Author

Abstract

Background: Chronic viral hepatitis, caused predominantly by hepatitis B virus (HBV) and hepatitis C virus (HCV), constitutes one of the most significant infectious disease burdens globally, accounting for an estimated 1.1 million deaths annually. Despite the availability of effective antiviral therapies and a prophylactic vaccine for HBV, the majority of infected individuals remain undiagnosed and untreated, perpetuating the hepatic sequelae of progressive fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).

References

1. GBD 2019 Hepatitis Collaborators. Mortality due to cirrhosis and liver cancer attributable to hepatitis B and C in 195 countries, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796-829. doi:10.1016/S2468-1253(22)00144-4

2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660

3. World Health Organization. Global Health Sector Strategies on, Respectively, HIV, Viral Hepatitis and Sexually Transmitted Infections for the Period 2022-2030. Geneva: WHO; 2022.

4. World Health Organization. Hepatitis C. WHO Fact Sheet. 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

5. Pawlotsky JM. Treatment of chronic hepatitis C virus infection in the era of direct-acting antiviral agents. J Hepatol. 2023;78(5):1054-1063. doi:10.1016/j.jhep.2022.12.014

6. Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. J Hepatol. 2017;67(4):847-861. doi:10.1016/j.jhep.2017.05.008

7. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383-403. doi:10.1016/S2468-1253(18)30056-6

8. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212-2219. doi:10.1016/j.vaccine.2011.12.116

9. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398. doi:10.1016/j.jhep.2017.03.021

10. Ray Kim W. Global epidemiology and burden of hepatitis C. Microbes Infect. 2002;4(12):1219-1225. doi:10.1016/S1286-4579(02)01649-0

11. Lazarus JV, Safreed-Harmon K, Hetherington KL, et al. Consensus statements on reorienting health and social systems to optimise hepatitis C elimination. J Hepatol. 2021;74(3):489-498. doi:10.1016/j.jhep.2020.10.038

12. Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1 Suppl):S84-S101. doi:10.1016/j.jhep.2016.02.021

13. Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol. 2016;64(1 Suppl):S71-S83. doi:10.1016/j.jhep.2016.01.026

14. Rehermann B, Thimme R. Insights from antiviral T cell responses in acute and chronic hepatitis B and C virus infection. Gastroenterology. 2019;156(2):369-383. doi:10.1053/j.gastro.2018.10.024

15. Manns MP, Buti M, Gane E, et al. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. doi:10.1038/nrdp.2017.6

16. Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151(1):70-86. doi:10.1053/j.gastro.2016.04.003

17. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749-1761. doi:10.1016/S0140-6736(14)60121-5

18. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. doi:10.1002/hep.29800

19. Chevaliez S, Pawlotsky JM. New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings. J Hepatol. 2018;69(4):916-926. doi:10.1016/j.jhep.2018.05.017

20. Germer JJ, Beito TL, Espy MJ, et al. Comparison of the COBAS AmpliPrep/COBAS TaqMan hepatitis B virus (HBV) test and COBAS AmpliPrep/COBAS TaqMan HBV test v2.0 for quantification of HBV DNA. J Clin Microbiol. 2012;50(3):1045-1048. doi:10.1128/JCM.05773-11

21. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. doi:10.1016/j.jhep.2015.11.004

22. Toshima T, Shirabe K, Ikegami T, et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), for assessing liver fibrosis in non-alcoholic fatty liver disease. PLoS One. 2015;10(3):e0121197. doi:10.1371/journal.pone.0121197

23. Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398. doi:10.1016/j.jhep.2017.03.021

24. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297-1309. doi:10.1053/j.gastro.2017.02.009

25. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553-562. doi:10.1038/nrgastro.2013.107

26. Thursz M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol. 2014;11(1):28-35. doi:10.1038/nrgastro.2013.179

27. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477-1492. doi:10.1093/cid/ciy585

28. Younossi ZM, Tanaka A, Eguchi Y, et al. The impact of hepatitis C virus outside the liver: evidence from Asia. Liver Int. 2017;37(2):159-172. doi:10.1111/liv.13167

29. Dusheiko G, Aghemo A, Bhagat S, et al. New approaches to achieving a cure for hepatitis B. J Hepatol. 2024;80(3):483-495. doi:10.1016/j.jhep.2023.10.026

30. Thursz MR, Gane E, Schwabe R, Hellard M, Estes C. New challenges, new approaches: roadmap for the elimination of viral hepatitis. J Hepatol. 2021;74(Suppl 1):S52-S68. doi:10.1016/j.jhep.2021.01.014

31. Рахматуллаева, Ш. Б., Муминова, М. Т., Нурматов, А. Х., & Саъдуллаев, С. Э. (2023). Особенности течения COVID-19 у детей с коморбидной патологией. Педиатрия. Восточная Европа,(3 Часть 12), 436-442.

32. Матякубов, Б. Б., & Ниязметов, Р. Э. СОВРЕМЕННЫЕ АСПЕКТЫ ЛЕЧЕНИЯ МАССИВНОГО АКУШЕРСКОГО КРОВОТЕЧЕНИЯ В ИССЛЕДУЕМОЙ ГРУППЕ. МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ РЕСПУБЛИКИ УЗБЕКИСТАН РЕСПУБЛИКАНСКИЙ СПЕЦИАЛИЗИРОВАННЫЙ НАУЧНО-ПРАКТИЧЕСКИЙ МЕДИЦИНСКИЙ ЦЕНТР АКУШЕРСТВА И ГИНЕКОЛОГИИ АССОЦИАЦИЯ ВРАЧЕЙ ЧАСТНОЙ ПРАКТИКИ УЗБЕКИСТАНА КЛИНИКА «MAHLIYO-SHIFO» & V, 23.

33. NIYAZMETOV, R., MATYAKUBOV, B., NAZAROV, B., & USINOVA, Z. MASSIVE OBSTETRIC BLEEDING: OPTIMIZATION OF TOTAL HYSTERECTOMY SURGERY TECHNIQUE AND CONSERVATIVE TREATMENT. INFUSION & CHEMOTHERAPY Учредители: Communicable Diseases Intensive Care Association, (3.1), 55-56.

34. Максумова, Н. Б., Ниязметов, Р. Э., Матякубов, Б. Б., & Усинова, З. Б. (2019). РОЛЬ МЕСТНОГО ИСПОЛЬЗОВАНИЯ КОНЪЮГИРОВАННОГО ЭСТРОГЕНА В УЛУЧШЕНИИ ИСХОДОВ ОПЕРАТИВНОГО ЛЕЧЕНИЯ ПРОЛАПСА ГЕНИТАЛИЙ. Innova, (2 (15)), 20-23.

35. Matyakubov, B. B., Niyazmetov, R. E., Khabibullaev, D. M., & Usinova, Z. B. (2021). SURGICAL TACTICS FOR MASSIVE OBSTETRIC BLEEDING. European Journal of Molecular and Clinical Medicine, 8(2), 594-600.